Sudeep Pharma Ltd. IPO Details – Price, Date, GMP & Analysis
Sudeep Pharma Ltd. IPO Overview
Company Overview
Sudeep Pharma Limited, incorporated in 1989, manufactures pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, serving over 100 countries. The company operates six manufacturing facilities with a production capacity of 50,000 MT, specializing in minerals like calcium, iron, magnesium, zinc, potassium, and sodium. It supplies over 200 products to various sectors, including pharma, food, and nutrition, and has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients. As of December 31, 2024, the company employed 704 permanent staff.
IPO Timeline
Opens
Nov 21
Closes
Nov 25
Allotment
Nov 26
Refunds
Nov 27
Shares Credit
Nov 27
Listing
Nov 28
Opens
Nov 21
Closes
Nov 25
Allotment
Nov 26
Refunds
Nov 27
Shares Credit
Nov 27
Listing
Nov 28
Latest Subscription Data
| Category | Subscription | Status |
|---|---|---|
| QIB (Qualified Institutional Buyers) | 213.08x | Oversubscribed |
| NII (Non-Institutional Investors/HNI) | 116.72x | Oversubscribed |
| RII (Retail Individual Investors) | 15.65x | Oversubscribed |
| Total Subscription | 93.71x | Oversubscribed |
Last updated: Nov 25, 2025, 06:21 PM
Financial Information
Financial Data Table
Detailed breakdown of financial metrics across years
| Financial Metric | 2025 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Assets | ₹717.17 Cr | ₹717.17 Cr | ₹513.87 Cr | ₹420.11 Cr |
| EBITDA | ₹199.28 Cr | ₹199.28 Cr | ₹187.76 Cr | ₹98.64 Cr |
| NET Worth | ₹497.53 Cr | ₹497.53 Cr | ₹359.07 Cr | ₹226.29 Cr |
| Profit After Tax | ₹138.69 Cr | ₹138.69 Cr | ₹133.15 Cr | ₹62.32 Cr |
| Reserves and Surplus | ₹481.11 Cr | ₹481.11 Cr | ₹354.59 Cr | ₹221.88 Cr |
| Total Borrowing | ₹135.25 Cr | ₹135.25 Cr | ₹75.03 Cr | ₹82.26 Cr |
| Total Income | ₹511.33 Cr | ₹511.33 Cr | ₹465.38 Cr | ₹438.26 Cr |
Strengths & Risks Analysis
Key Risks
Potential challenges and risk factors
- Top 10 customers contribute 35%+ of revenue, posing concentration risk.
- 60%+ revenue from one segment poses concentration risk.
- Quality lapses or audit failures may lead to order loss and reputational harm.
- Operational concentration in Gujarat exposes the business to regional disruption risks.
- Delays or failures in new product launches may impact growth and profitability.
- Unsuccessful acquisitions may strain resources and dilute expected synergies.
- Regulatory and government approval delays may disrupt operations.
IPO Details
Sudeep Pharma IPO Details
| Face Value | ₹1 per share |
| Fresh Issue | 16,02,023 shares (aggregating up to ₹95.00 Cr) |
| IPO Date | November 21, 2025 to November 25, 2025 |
| Issue Price Band | ₹563 to ₹593 per share |
| Issue Price Final | ₹593 per share |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Listing Date | November 28, 2025 |
| Lot Size | 25 Shares |
| Offer for Sale | 1,34,90,726 shares of ₹1 (aggregating up to ₹800.00 Cr) |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Share Holding Post Issue | 11,29,48,625 shares |
| Share Holding Pre Issue | 11,13,46,602 shares |
| Total Issue Size | 1,50,92,749 shares (aggregating up to ₹895.00 Cr) |
Sudeep Pharma IPO Reservation
Share Reservation Distribution
Sudeep Pharma IPO Promoter Holding
| Promoter Holding Post Issue | 76.15% |
| Promoter Holding Pre Issue | 89.37% |
Sudeep Pharma IPO Listing Details
| BSE Script Code | 544619 |
| Final Issue Price | ₹593 per share |
| ISIN | INE0QPI01025 |
| Listing Date | November 28, 2025 |
| NSE Listing Group | EQ (Rolling) |
| NSE Symbol | SUDEEPPHRM |
Key Dates
